...
首页> 外文期刊>Bioorganic and medicinal chemistry >Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines
【24h】

Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines

机译:盐酸二乙胺的二硫代氨基甲酸酯衍生物在前列腺癌细胞系中的设计,合成和细胞毒性研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A small library of emetine dithiocarbamate ester derivatives were synthesized in 25-86% yield via derivatization of the N2'-position of emetine. Anticancer evaluation of these compounds in androgen receptor positive LNCaP and androgen receptor negative PC3 and DU145 prostate cancer cell lines revealed time dependent and dose-dependent cytotoxicity. With the exception of compound 4c, all the dithiocarbamate ester analogs in this study showed appreciable potency in all the prostate cancer cell lines (regardless of whether it is androgen receptor positive or negative) with a cytotoxicity IC50 value ranging from 1.312 +/- 0.032 mu M to 5.201 +/- 0.125 mu M by day 7 of treatment. Compared to the sodium dithiocarbamate salt 1, all the dithiocarbamate ester analogs (2 and 4a-4g) displayed lower cytotoxicity than compound 1 (PC3, IC50 = 0.087 +/- 0.005 mu M; DU145, IC50 = 0.079 +/- 0.003 mu M and LNCaP, IC50 = 0.079 +/- 0.003 mu M) on day 7 of treatment. Consequently, it appears that S-alkylation of compound 1 leads to a more stable dithiocarbamate ester derivative that resulted in lower anticancer activity in the prostate cancer cell lines. (C) 2015 Elsevier Ltd. All rights reserved.
机译:通过将依替丁胺的N2'-位衍生化,合成了一个少量的依替丁二硫代氨基甲酸酯衍生物库,其收率为25-86%。这些化合物在雄激素受体阳性LNCaP和雄激素受体阴性PC3和DU145前列腺癌细胞系中的抗癌评估显示出时间依赖性和剂量依赖性细胞毒性。除化合物4c外,本研究中的所有二硫代氨基甲酸酯类似物在所有前列腺癌细胞系中均显示出显着的效力(无论是雄激素受体阳性还是阴性),其细胞毒性IC50值范围为1.312 +/- 0.032μm在治疗的第7天,M为5.201 +/- 0.125μM。与二硫代氨基甲酸钠盐1相比,所有二硫代氨基甲酸酯类似物(2和4a-4g)显示出比化合物1低的细胞毒性(PC3,IC50 = 0.087 +/- 0.005μM; DU145,IC50 = 0.079 +/- 0.003μM和LNCaP,治疗第7天的IC50 = 0.079 +/- 0.003μM)。因此,似乎化合物1的S-烷基化导致更稳定的二硫代氨基甲酸酯衍生物,其导致前列腺癌细胞系中较低的抗癌活性。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号